A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.

Trial Details

NCT ID
NCT07610798
Phase
PHASE1 / PHASE2
Sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • INV-8989
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Written informed consent obtained.
  • Adult patients aged ≥ 18 years.
  • Patients with histologically or cytologically confirmed locally advanced, unresectable, or metastatic solid tumors harboring the KRAS G12D mutations.
  • Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →